公开(公告)号：WO2023057875A1

公开(公告)日：2023-04-13

申请号：PCT/IB2022/059416

申请日：2022-10-03

申请人： EUROPEAN BRAIN RESEARCH INSTITUTE (EBRI) R. LEVI MONTALCINI

发明人： CATTANEO, Antonino ,  MALERBA, Francesca

IPC分类号： G01N33/68 ,  B01L3/00 ,  G01N27/447 ,  G01N2333/48 ,  G01N2800/2814 ,  G01N2800/2821 ,  G01N2800/2835 ,  G01N2800/285 ,  G01N33/6896

摘要： Method for the early diagnosis and the monitoring of the evolution/regression of neurodegenerative pathologies, said method providing for the quantification of a. biomarker for said pathologies in a fluid that was previously drawn from a. patient, said fluid being selected from among: cerebrospinal fluid; serum; urine; post mortem cerebral tissues and cellular lysates, said method being characterized in that the quantified biomarker is selected from among native proNGF; modified proNGF, the latter being proNGF in its forms with higher molecular weight, including forms of 39-40 kDa and 45-50kDa; NGF; and the proNGF/NGF ratio, said method sequentially providing for the fol lowing steps of Preparation of the biological sample, Definition of the calibration curve; Execution of run and interpolation.

公开(公告)号：WO2023010076A1

公开(公告)日：2023-02-02

申请号：PCT/US2022/074255

申请日：2022-07-28

申请人： ALECTOR LLC

发明人： PINCETIC, Andrew ,  ROSENTHAL, Arnon

IPC分类号： A61P21/00 ,  A61P25/28 ,  A61P29/00 ,  A61P37/06 ,  C07K16/28 ,  G01N33/50 ,  A61K39/00 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2800/24 ,  G01N33/6896

摘要： The present disclosure provides antibodies and antibody fragments that bind to human SIRPA. In some embodiments, the antibodies are SIRPA agonists. The antibodies and antibody fragments disclosed herein may be used for the treatment and/or diagnosis of diseases, disorders, and conditions associated with reduced SIRPA activity.

公开(公告)号：WO2022189442A1

公开(公告)日：2022-09-15

申请号：PCT/EP2022/055919

申请日：2022-03-08

申请人： EM SCIENTIFIC LIMITED

发明人： SIRKA, Ernestas ,  CRYAR, Adam

IPC分类号： G01N33/68 ,  G01N2800/2835 ,  G01N2800/52 ,  G01N33/6848 ,  G01N33/6896

摘要： The present invention relates to a method for assessing the efficacy a treatment for a neurodegenerative disease in a subject wherein the presence of said proteolytic peptide is assayed for using mass spectrometry with reference to a corresponding labelled and/or unlabelled reference proteolytic peptide. The invention also relates to a method for stratifying a subject having a neurodegenerative disease, a method for the diagnosis of a neurodegenerative disease, methods for the treatment of a subject having a neurodegenerative disease and a kit for assessing the efficacy of a first-line treatment for a neurodegenerative disease in a subject.

公开(公告)号：WO2022133107A8

公开(公告)日：2022-06-23

申请号：PCT/US2021/063843

申请日：2021-12-16

申请人： COGNEXT DIAGNOSTICS LLC ,  THE JOHNS HOPKINS UNIVERSITY

发明人： WORLEY, Paul, F. ,  XIAO, Meifang ,  XU, Desheng

IPC分类号： G01N33/68 ,  C07K16/18 ,  G01N33/566 ,  G01N33/53 ,  C12Q1/6804 ,  C12Q1/6851 ,  G01N2800/2814 ,  G01N2800/52 ,  G01N33/6896

摘要： Disclosed herein are methods for diagnosing a subject as having a neurological disorder, such as Alzheimer's disease, using proximity-based detection assays capable of detecting complexes containing two or more synaptic proteins, such as neuronal pentraxins, from a blood, cerebrospinal fluid, or other fluid sample of the subject. Also disclosed are methods of evaluating and monitoring subjects having or at risk of developing a neurological disorder using the aforementioned assays.

公开(公告)号：WO2022104136A2

公开(公告)日：2022-05-19

申请号：PCT/US2021/059240

申请日：2021-11-12

申请人： CHILDREN'S MEDICAL CENTER CORPORATION

发明人： STEEN, Judith AJ ,  STEEN, Hanno ,  WESSELING, Hendrik ,  KUMAR, Mukesh ,  MAIR, Waltraud ,  BEEREPOOT, Pieter

IPC分类号： C12Q1/37 ,  G01N30/72 ,  G01N33/68 ,  G01N2333/4709 ,  G01N2440/10 ,  G01N2440/14 ,  G01N2440/36 ,  G01N2800/2821 ,  G01N33/6896

摘要： This disclosure relates to methods for diagnosing and treating a tauopathy, e.g., Alzheimer's disease, in a subject, the methods comprising, in part, identifying one or more post-translation modifications (PTMs) in the subject.

公开(公告)号：WO2022100920A1

公开(公告)日：2022-05-19

申请号：PCT/EP2021/076872

申请日：2021-09-29

申请人： FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA DEL HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL

发明人： VILLAR GUIMERANS, Luisa María ,  WALO DELGADO, Paulette Esperanza ,  MEDINA HERAS, Silvia ,  MONREAL LAGUILLO, Enrique ,  COSTA-FROSSARD FRANÇA, Lucienne ,  SAINZ DE LA MAZA CANTERO, Susana

IPC分类号： G01N33/564 ,  G01N33/6896

摘要： The objective of the present invention is determining if a Multiple sclerosis (MS) patient´s blood lymphocyte profile before alemtuzumab treatment initiation could identify patients with an increased risk of developing later autoimmunity. We herein describe, for the first time, that the B/4TNF ratio can be a useful tool to stratify the risk of autoimmunity in MS patients who are going to initiate alemtuzumab treatment.

公开(公告)号：WO2021239700A2

公开(公告)日：2021-12-02

申请号：PCT/EP2021/063833

申请日：2021-05-25

申请人： FORSCHUNGSZENTRUM JÜLICH GMBH

发明人： TAMGÜNEY, Gültekin ,  WILLBOLD, Dieter ,  PILS, Marlene ,  BANNACH, Oliver

IPC分类号： G01N33/68 ,  G01N2333/4709 ,  G01N2800/2821 ,  G01N33/6896

摘要： Die Erfindung betrifft Verfahren zur selektiven Quantifizierung von A-beta- bzw. alpha-Synuclein-Aggregaten umfassend die Immobilisierung von Anti-A-beta- bzw. alpha-Synuclein-Antikörper auf einem Substrat, Auftragen der zu untersuchenden Stuhlprobe auf das Substrat, Hinzufügen von für die Detektion gekennzeichneten Sonden, die durch spezifische Bindung an A-beta- bzw. alpha-Synuclein-Aggregate diese markieren und Detektion der markierten Aggregate.

公开(公告)号：WO2021130310A1

公开(公告)日：2021-07-01

申请号：PCT/EP2020/087763

申请日：2020-12-23

申请人： THE ROYAL COLLEGE OF SURGEONS IN IRELAND ,  UNIVERSITY COLLEGE DUBLIN

发明人： COTTER, David ,  MONGAN, David ,  CANNON, Mary ,  CAGNEY, Gerard

IPC分类号： G01N33/68 ,  G01N2800/30 ,  G01N2800/50 ,  G01N2800/52 ,  G01N33/6896

摘要： The invention relates to a method of determining the likelihood of an individual transitioning to a first episode of psychosis (FEP), the method comprising determining the level of selected markers in a bodily fluid sample from the individual, wherein the increase or decrease in the markers is predictive of the individual transitioning to a first episode of psychosis (FEP). The invention also relates to a method of predicting the functional outcome for an individual following a first episode of psychosis (FEP), the method comprising determining the level of selected markers in a bodily fluid sample from the individual, wherein the increase or decrease in the markers is predictive of an increased risk of functional disability outcome for the individual.

公开(公告)号：WO2021024209A1

公开(公告)日：2021-02-11

申请号：PCT/IB2020/057415

申请日：2020-08-05

申请人： APRINOIA THERAPEUTICS INC.

发明人： JANG, Ming-Kuei ,  TAI, Chin-Yin

IPC分类号： C07K16/18 ,  C07K14/47 ,  A61P25/28 ,  A61K39/00 ,  A61K2039/505 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6843 ,  C07K14/4711 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  G01N33/6896

摘要： The present disclosure relates to antibodies that bind selectively to pathological Tau, including compositions and methods relating to such antibodies, such as for treating tauopathies, neurodegenerative diseases associated with pathological aggregation of Tau.

公开(公告)号：WO2023275590A1

公开(公告)日：2023-01-05

申请号：PCT/IB2021/055806

申请日：2021-06-29

申请人： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.

发明人： SHARON, Ronit ,  SCHECHTER, Meir ,  ABD ALHADI, Suad

IPC分类号： G01N33/68 ,  G01N2800/2835 ,  G01N33/6896

摘要： The present invention is directed to a method for determining a subject is afflicted with or having increased risk of developing an alpha-synuclein–associated disease or disorder, Parkinson's disease, or both. The method further includes administering to the subject determined as being afflicted with or having increased risk of developing an alpha-synuclein–associated disease or disorder a therapeutically effective amount of an agent characterized by being capable of decreasing signaling transduced by a member of PI4,5P2 signal transduction pathway.